CY1112270T1 - Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης - Google Patents

Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης

Info

Publication number
CY1112270T1
CY1112270T1 CY20121100081T CY121100081T CY1112270T1 CY 1112270 T1 CY1112270 T1 CY 1112270T1 CY 20121100081 T CY20121100081 T CY 20121100081T CY 121100081 T CY121100081 T CY 121100081T CY 1112270 T1 CY1112270 T1 CY 1112270T1
Authority
CY
Cyprus
Prior art keywords
renal
useful
hyponatremia
hypertension
insufficiency
Prior art date
Application number
CY20121100081T
Other languages
Greek (el)
English (en)
Inventor
Min A Xiang
Mona Patel
Philip Rybczynski
Joseph Gunnet
Keith T Demarest
Richard Look
Bruce Maryanoff
Michael J Costanzo
Stephen C Yabut
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1112270T1 publication Critical patent/CY1112270T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CY20121100081T 2006-09-22 2012-01-24 Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης CY1112270T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82665406P 2006-09-22 2006-09-22
EP07842799A EP2078022B1 (en) 2006-09-22 2007-09-19 Spiro benzazepines used as vasopressin antagonists

Publications (1)

Publication Number Publication Date
CY1112270T1 true CY1112270T1 (el) 2015-12-09

Family

ID=39030853

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100081T CY1112270T1 (el) 2006-09-22 2012-01-24 Σπειρο βενζαζεπινες χρησιμες ως ανταγωνιστες αγγειοπιεσινης

Country Status (14)

Country Link
US (1) US7825110B2 (enExample)
EP (1) EP2078022B1 (enExample)
JP (1) JP2010504351A (enExample)
CN (1) CN101541806A (enExample)
AT (1) ATE532786T1 (enExample)
AU (1) AU2007299818B2 (enExample)
CA (1) CA2665849A1 (enExample)
CY (1) CY1112270T1 (enExample)
DK (1) DK2078022T3 (enExample)
ES (1) ES2374582T3 (enExample)
PL (1) PL2078022T3 (enExample)
PT (1) PT2078022E (enExample)
SI (1) SI2078022T1 (enExample)
WO (1) WO2008036755A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
ES2686326T3 (es) 2014-07-15 2018-10-17 Grünenthal GmbH Derivados de azaspiro(4,5)decano sustituidos
BR112017026173A2 (pt) 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich
KR102790657B1 (ko) * 2017-09-15 2025-04-02 아제반 파마슈티칼스, 인코퍼레이티드 뇌 손상을 치료하기 위한 조성물 및 방법
WO2019141575A1 (de) 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Unterstützung bei der behandlung von herzinsuffizienz
US12698266B2 (en) 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
TW202220958A (zh) * 2020-08-07 2022-06-01 美商卡司馬療法公司 Ｔｒｐｍｌ調節劑
JP7627343B2 (ja) * 2020-11-26 2025-02-05 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド 新規ベンズアゼピンスピロ環式誘導体
CN112939864B (zh) * 2021-01-29 2022-05-06 中国医科大学 螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
EP4491699A1 (de) 2023-07-13 2025-01-15 Klueber Lubrication München GmbH & Co. KG Phthalimidverbindungen als basisöl für schmierstoffzusammensetzungen
WO2026002248A1 (zh) * 2024-06-28 2026-01-02 上海济煜医药科技股份有限公司 作为v2受体拮抗剂的苯并氮杂卓并环衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
JPH08502474A (ja) 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
ES2250432T3 (es) * 2000-07-05 2006-04-16 Ortho-Mcneil Pharmaceutical, Inc. Espirobenzoazepinas no peptidicas sustituidas, antagonistas de la vasopresina.
AU2002231098A1 (en) * 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
US7011898B2 (en) * 2003-03-21 2006-03-14 Air Products And Chemicals, Inc. Method of joining ITM materials using a partially or fully-transient liquid phase
CA2529513A1 (en) * 2003-06-17 2005-01-06 Janssen Pharmaceutica N.V. Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
SI1633719T1 (sl) * 2003-06-17 2010-01-29 Janssen Pharmaceutica Nv Substituirani spirobenzazepini
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid

Also Published As

Publication number Publication date
PT2078022E (pt) 2012-01-11
CN101541806A (zh) 2009-09-23
AU2007299818B2 (en) 2012-08-02
ATE532786T1 (de) 2011-11-15
PL2078022T3 (pl) 2012-04-30
WO2008036755A1 (en) 2008-03-27
DK2078022T3 (da) 2012-02-13
EP2078022A1 (en) 2009-07-15
JP2010504351A (ja) 2010-02-12
ES2374582T3 (es) 2012-02-20
US7825110B2 (en) 2010-11-02
CA2665849A1 (en) 2008-03-27
SI2078022T1 (sl) 2012-01-31
AU2007299818A1 (en) 2008-03-27
EP2078022B1 (en) 2011-11-09
US20080076753A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
ATE532786T1 (de) Spirobenzazepine als vasopressinantagonisten
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
EA201070339A1 (ru) Активаторы растворимой гуанилатциклазы
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
EA200900811A1 (ru) Имидазолы в качестве ингибиторов альдостеронсинтазы
CO6220853A2 (es) Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios
MY128065A (en) Tricyclic benzodiazepines as vasopressin receptor antagonists
EA201100299A1 (ru) Органические соединения
MA35032B1 (fr) Derives de glycoside et leurs utilisations dans le traitement du diabete
DOP2010000302A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CY1109585T1 (el) Υποκατεστημενες σπειροβενζαζεπινες
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
DK1307430T3 (da) Ikke-peptidsubstituerede spirobenzoazepiner som vasopressin-antagonister
ATE557019T1 (de) Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten
PT1214323E (pt) Indoloazepinas como antagonistas do receptor de vasopressina
MA32512B1 (fr) Derive de phenanthrenone, compositions et procedes
WO2006049984A3 (en) Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists
YU32702A (sh) Nepeptidni supstituisani benzotiazepini kao antagonisti vazopresina
MA34462B1 (fr) Composes de thiophene 2,3,5- trisubstitues et leurs utilisations